Disclosed herein is a long acting pharmaceutical composition for treating or preventing human immunodeficiency virus (HIV) infection. The pharmaceutical composition comprises a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier; wherein the lysine-based aspartyl protease inhibitor or salt thereof has an average effective particle size of less than about 500 nm. A method for treating or preventing HIV infection with the pharmaceutical composition is also disclosed.

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

A treatment solution includes a carrier liquid, and an antifungal agent comprising on of tolnaftate, terbinafine hydrochloride, and miconazole nitrate, the antifungal agent having a concentration of at least 1 wt % of the solution, wherein the treatment solution is alcohol free.

A treatment solution includes a carrier liquid, and an antifungal agent comprising on of tolnaftate, terbinafine hydrochloride, and miconazole nitrate, the antifungal agent having a concentration of at least 1 wt % of the solution, wherein the treatment solution is alcohol free.

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

A treatment solution contains a topical anesthetic, an anesthetic solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution contains an antifungal agent, a topical anesthetic, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution contains a topical anesthetic, an anesthetic solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution. A treatment solution contains an antifungal agent, a topical anesthetic, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution.